HemoClear
The Challenge
Despite its broad applicability, allogeneic (donor) red blood cell transfusion is associated with health risks, high treatment costs, and scarcity……
The Solution
Patient Blood Management (PBM) reduces the use of donor blood. Using a patient’s own [Autologous] blood for transfusion is a valuable PBM tool…….
About Us
Mission
HemoClear is a leading medical device manufacturing company that is dedicated to pursuing innovation in the development of practical and highly effective medical devices. Our mission is to offer new and reliable solutions for treating severe or life-threatening diseases.
Team
At HemoClear we work with the best and brightest people in their field in a diverse and inclusive organization where everybody contributes, irrespective of cultural, ethnic, or religious background, gender, sexual orientation, health, and age.
Vacancies
At our company, we firmly believe that a vibrant and inclusive company culture is the foundation for success. We strive to create an environment that not only values the expertise and skills of our employees but also encourages them to share their thoughts, feelings, and suggestions openly.
object(WP_Post)#12768 (24) {
["ID"]=>
int(5051)
["post_author"]=>
string(1) "2"
["post_date"]=>
string(19) "2025-10-10 16:00:58"
["post_date_gmt"]=>
string(19) "2025-10-10 16:00:58"
["post_content"]=>
string(614) "
HemoClear is a breakthrough micro-filtration system that enables high-quality, gravity-driven cell salvage, without the need for machines or electricity. Designed for simplicity, mobility, and performance in the OR.
HemoClear recovers high volumes of red cell and platelets!
Ideal for both pediatric and adult spine surgeries, HemoClear supports reduced transfusion rates, lower surgical costs, and fewer complications, empowering safer, more efficient care.
Learn more https://www.hemoclear.com/
Cell salvage reduces transfusions in complex scoliosis surgeries. What if you had access to that capability with greater flexibility and ease?
HemoClear is a breakthrough micro-filtration system that enables high-quality, gravity-driven cell salvage, without the need for machines or electricity. Designed for simplicity, mobility, and performance in the OR.
object(WP_Post)#12793 (24) {
["ID"]=>
int(5048)
["post_author"]=>
string(1) "2"
["post_date"]=>
string(19) "2025-10-10 15:57:44"
["post_date_gmt"]=>
string(19) "2025-10-10 15:57:44"
["post_content"]=>
string(751) "
With breakthrough cell salvage technology like HemoClear, patients can receive their own freshly micro-filtered blood, right in the OR or recovery room. No machines, no electricity, no donor blood needed.
HemoClear empowers clinicians to deliver:
🔹Platelet-rich transfusion blood.
🔹100% biologically compatible transfusions
🔹 Ultra-low risk of transfusion-related infections or immune reactions
🔹 Simpler workflows, no crossmatch or complex logistics
🔹 Patient's independence from donor systems
This next-generation patient blood management makes blood transfusion safer, smarter, and sustainable.
What if patients didn’t have to rely on others for life-saving blood?
With breakthrough cell salvage technology like HemoClear, patients can receive their own freshly micro-filtered blood, right in the OR or recovery room. No machines, no electricity, no donor blood needed.
object(WP_Post)#12792 (24) {
["ID"]=>
int(5045)
["post_author"]=>
string(1) "2"
["post_date"]=>
string(19) "2025-10-10 15:55:37"
["post_date_gmt"]=>
string(19) "2025-10-10 15:55:37"
["post_content"]=>
string(876) "
In a recently published case report, we explore the successful treatment of myasthenia gravis (MG) following long COVID in a 71-year-old patient, using HemoClear gravity-driven plasma exchange.
Despite initial deterioration and resistance to standard therapy, the patient showed marked clinical improvement following low-volume plasmapheresis using HemoClear’s straightforward and cost-effective gravity-driven microfiltration technology.
This case highlights the value of accessible innovations like HemoClear in managing complex post-COVID autoimmune conditions, where conventional treatments may be unavailable.
Read the full case: https://bit.ly/3Hxwr7m
Efficacy of Plasma Exchange in Myasthenia Gravis Following Long COVID in a Resource-Limited Context
New Publication Alert
In a recently published case report, we explore the successful treatment of myasthenia gravis (MG) following long COVID in a 71-year-old patient, using HemoClear gravity-driven plasma exchange.